Danyelza Injection 40 Mg

Danyelza Injection 40 Mg Specification

Packaging Type
Vial

Indication
Relapsed or Refractory Neuroblastoma

Salt Composition
Naxitamab-gqgk 40 mg

Life Span
24 Months

Pacakaging (Quantity Per Box)
1 Vial per Box

Dosage Form
Injection

Brand Name
Danyelza

Drug Type
Prescription

Ingredients
Naxitamab-gqgk

Physical Form
Injection

Function
Antibody Therapy

Recommended For
Neuroblastoma Patients

Dosage
40 mg per vial

Dosage Guidelines
As Directed by Physician

Suitable For
Adults and Children

Quantity
1 Vial

Storage Instructions
Keep In A Cool And A Dry Place

Appearance
Sterile Solution

Box Contains
Single Use Vial

Clinical Use
Oncology Therapy

Therapeutic Area
Pediatric Cancer

Route of Administration
Intravenous

Prescription Status
Rx Only

Reconstitution Required
Yes

Danyelza Injection 40 Mg Trade Information

Minimum Order Quantity
1 Vial

Supply Ability
5000 Vials Per Month

Delivery Time
2-10 Days

About Danyelza Injection 40 Mg

Danyelza Injection 40 Mg stands as a best-seller and elite offering in the realm of pediatric oncology. Highlighted for its flawless formulation, this preeminent antibody therapy contains 40 mg of naxitamab-gqgk per sterile, single-use vial. Its majestic efficacy is tailored for patients battling relapsed or refractory neuroblastoma. Exclusively available on prescription, Danyelza is suitable for both adults and children, administered intravenously after reconstitution. It remains stable for up to 24 months under optimal, dry storage. Trusted by oncologists, Danyelza represents a remarkable innovation in pediatric cancer care.

Competitive Advantages & Key Features of Danyelza Injection 40 Mg

Danyelza Injection 40 Mg is acclaimed for its rapid action against neuroblastoma and exceptional safety profile. Its single-use, sterile vial ensures convenient handling and minimal wastage. As an elite monoclonal antibody therapy, Danyelza achieves robust response rates where traditional treatments falter. The flawless preparation process guarantees optimal potency, aligning with global quality benchmarks. Danyelza's pediatric focus, broad suitability, and easy intravenous administration mark it as a highlighted choice among advanced oncology solutions.

Certifications, Outlay, and Packaging Details for Danyelza Injection 40 Mg

Certified to meet preeminent pharmaceutical standards, Danyelza Injection is available from India's trusted suppliers, exporters, and wholesalers. The outlay covers fully compliant, secure goods transport and robust packaging-each vial preserved in a high-quality box to minimize potential expenditure due to spoilage. FOB port arrangements are flexible, tailored for efficient international shipping. Every 1-vial box is professionally labeled for accurate inventory management and seamless logistics from warehouse to healthcare provider.

FAQ's of Danyelza Injection 40 Mg:

Q: How is Danyelza Injection 40 Mg administered to patients?

A: Danyelza Injection 40 Mg must be reconstituted and then administered intravenously by healthcare professionals, following physician-directed dosage guidelines.

Q: What is the primary clinical use of Danyelza Injection 40 Mg?

A: Danyelza Injection is primarily used for the treatment of relapsed or refractory neuroblastoma in both children and adults within oncology therapy.

Q: When should Danyelza Injection be considered for neuroblastoma patients?

A: Danyelza is indicated for patients who have experienced relapse or have refractory neuroblastoma, typically following unsuccessful conventional treatments.

Q: Where should Danyelza Injection 40 Mg be stored before use?

A: The vial should be kept in a cool, dry place as per storage instructions to maintain its stability and efficacy up to 24 months.

Q: What is the recommended process for preparing Danyelza Injection 40 Mg?

A: Before administration, the injection requires reconstitution by a qualified healthcare professional, ensuring a sterile environment and accurate preparation.

Q: How does Danyelza Injection 40 Mg benefit neuroblastoma patients compared to other therapies?

A: As a targeted antibody therapy, Danyelza offers enhanced effectiveness and safety in treating neuroblastoma, especially for patients who have not responded optimally to previous treatments.

Tell us about your requirement